Lallemand’s L. rhamnosus HA-114 supports during a weight management program

Brunella V. Gonzales Cautela (Lallemand) discusses the impact of L. rhamnosus HA-114 on a weight loss program for people suffering of obesity and overweight.

Industry, Video

Brunella V. Gonzalez Cautela, Clinical Research Specialist at Lallemand Health Solutions, discusses a randomized clinical trial conducted at the Université Laval in Canada to observe the impact of Lacticaseibacillus rhamnosus HA-114 on a weight loss program for participants suffering of obesity and overweight during a nutritional intervention.

Staff editor

Most recent

Scientific research

HCPs Area

World Microbiome Day 2023: Microbes and Food

Probiotics for female indications: Impact of Probi® probiotics for bone health support

Industry

Freya Biosciences secures $10.4 million investment to tackle women’s health challenges

Probiotics as adjuvant therapy in cancer immunotherapy: from Biofarma Group

Read more about Industry, Video

Nutrition

Lallemand’s L. rhamnosus HA-114 supports during a weight management program

Most recent

Understanding the gut microbiota in athletes

Microbial signatures for food traceability: ensuring quality and safety from fermented wines to novel insect-based foods

Freya Biosciences secures $10.4 million investment to tackle women’s health challenges

Probiotics as adjuvant therapy in cancer immunotherapy: from Biofarma Group

HCPs Area

World Microbiome Day 2023: Microbes and Food

Probiotics for female indications: Impact of Probi® probiotics for bone health support

Industry

Freya Biosciences secures $10.4 million investment to tackle women’s health challenges

Probiotics as adjuvant therapy in cancer immunotherapy: from Biofarma Group

Microbial signatures for food traceability: ensuring quality and safety from fermented wines to novel insect-based foods

Freya Biosciences secures $10.4 million investment to tackle women’s health challenges

Probiotics as adjuvant therapy in cancer immunotherapy: from Biofarma Group

QIAGEN and McGill University partner to drive innovation in microbiome research

Dietary fiber, bloutia, and mucus function: uncovering potential for Next-Generation Probiotics

EnteroBiotix’s EBX-102 shows promising Phase 1b results for liver cirrhosis treatment

October 2024 review: M&A, licensing, and investments in one place

The impact of food additives on the microbiome: pathways to personalized health